Therapeutic Results and Tissue Concentrations of Temocillin in Surgical Patients1

Wittke, Rolf R.; Adam, Dieter; Klein, Heidi E.

doi:10.2165/00003495-198500295-00049

Cited by 6 publications

(5 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our dataset includes 46 IAI, an indication poorly described in literature for the use of temocillin despite a few studies on its tissue penetration. 5–7 For this indication our study shows a clinical success rate of 91.3% when combined with metronidazole, which is comparable to the results of one study looking at temocillin use in critically unwell patients. 8 …”

Section: Discussionsupporting

confidence: 81%

Empirical use of temocillin in hospitalized patients: results from a retrospective audit

Kandil

Gray

El-Hamad

et al. 2023

JAC-Antimicrobial Resistance

View full text Add to dashboard Cite

Background Following a global shortage of piperacillin/tazobactam in 2017, a formulary decision was taken at a large District General Hospital in the East of England to partly replace piperacillin/tazobactam with either temocillin as monotherapy or as part of a combination regimen. A retrospective audit was then conducted to assess the clinical effectiveness of temocillin therapy. Methods Data from patients admitted to Watford General Hospital between May and August 2017 and treated with temocillin were reviewed retrospectively. Clinical characteristics of patients, data related to the episode of infection, clinical success, tolerance and mortality were analysed. Results Temocillin was used in 126 patients with median age of 73 years. Infection episodes mostly originated from the abdomen (n = 46), the lung (n = 40) and the urinary tract (n = 21). Seventy-seven patients received temocillin as first-line therapy and 106 received it empirically, with temocillin prescribed in combination with another antibiotic in 82% of the empirically treated cases. Clinical success was observed in 88.9% of cases with no difference between patients treated empirically and others (89.6% versus 85%) or in efficacy among abdominal (91%), pulmonary (87.5%) and urinary (81%) infections. One case of Clostridioides difficile infection was reported in a patient treated with four different antibiotics. During the shortage period, the hospital’s standardized mortality ratio was significantly lower when compared with the same period of the preceding year (85 versus 96). Conclusions Using temocillin as part of an empirical strategy is feasible and safe as long as appropriate antibiotic combination is recommended based upon the indication and the likely bacterial pathogen.

show abstract

Section: Discussionsupporting

confidence: 81%

Empirical use of temocillin in hospitalized patients: results from a retrospective audit

Kandil

Gray

El-Hamad

et al. 2023

JAC-Antimicrobial Resistance

View full text Add to dashboard Cite

show abstract

“…To the best of our knowledge, the reports that investigated the antibiotic concentration in the exudate of human skin defects and surgical wounds involved penicillins , cephalosporins and carbapenems , and in terms of anti‐MRSA drugs, the concentration of linezolid was only measured in blisters . We did not find any reports that investigated the migration of vancomycin into wound exudates.…”

Section: Discussionmentioning

confidence: 79%

Measurement of vancomycin hydrochloride concentration in the exudate from wounds receiving negative pressure wound therapy: a pilot study

Ida

Matsumura

Onishi

et al. 2014

International Wound Journal

View full text Add to dashboard Cite

It has been reported that negative pressure wound therapy (NPWT) is effective in the treatment of contaminated wounds. We hypothesised that systemically administered antibiotics migrate to wound site effectively by NPWT, which provides the antibacterial effect. We measured and compared the concentrations of vancomycin in the exudate and blood serum. Eight patients with skin ulcers or skin defect wounds who were treated with NPWT and were administered an intravenous drip of vancomycin were enrolled in this study. The wound surfaces were muscle, muscle fascia or adipose tissue. We administered vancomycin intravenously to NPWT patients (1-3 g/day). The exudate was obtained using 500 ml V.A.C. ATS canisters without gel. Three days later, the concentrations of vancomycin were measured. The mean concentration of vancomycin in the exudate from NPWT was 67% of the serum vancomycin concentration. We found that concentrations of vancomycin in NPWT exudates are higher than the previously reported concentrations in soft tissue without NPWT. The proactive use of NPWT might be considered in cases of suspected wound contamination when a systemic antibiotic is administered.

show abstract

“…Clinical efficacy was assessed as 'very good' in 23 patients. In one patient, there was a disorder of wound healing, and in another, staphylococcal bronchial pneumonia developed postoperatively [63]. Temocillin was tolerated very well, and no side effects were observed.…”

Section: Temocillin In Abdominal Infectionsmentioning

confidence: 91%

“…The median half-life was 3.86 (+/− 1.84) h. Mean concentrations of 12.44 and 38.59 mg/L were measured up to the 12th hour in the wound secretions and peritoneal secretions, respectively. In skin, fat, fascia, muscle, and gallbladder wall, temocillin concentrations greater than the inhibitory concentrations of most Gram-negative bacteria were demonstrated after one and two hours [63].…”

Section: Temocillin In Abdominal Infectionsmentioning

confidence: 96%

See 1 more Smart Citation

Temocillin: Applications in Antimicrobial Stewardship as a Potential Carbapenem-Sparing Antibiotic

et al. 2022

View full text Add to dashboard Cite

Temocillin is an old antibiotic, but given its particular characteristics, it may be a suitable alternative to carbapenems for treating infections due to ESBL-producing Enterobacterales and uncomplicated UTI due to KPC-producers. In this narrative review, the main research question was to summarize current evidence on temocillin and its uses in infectious diseases. A search was run on PubMed using the terms (‘Temocillin’ [Mesh]) AND (‘Infection’ [Mesh]). Current knowledge regarding temocillin in urinary tract infection, blood-stream infections, pneumonia, intra-abdominal infections, central nervous system infections, skin and soft tissues infections, surgical sites infections and osteoarticular Infections were summarized. Temocillin retain a favourable profile on microbiota and risk of Clostridioides difficile infections and could be an option for treating outpatients. Temocillin may be a valuable tool to treat susceptible pathogens and for which a carbapenem could be spared. Other advantages in temocillin use are that it is well-tolerated; it is associated with a low rate of C. difficile infections; it is active against ESBL, AmpC, and KPC-producing Enterobacterales; and it can be used in the OPAT clinical setting.

show abstract

Therapeutic Results and Tissue Concentrations of Temocillin in Surgical Patients1

Cited by 6 publications

References 1 publication

Empirical use of temocillin in hospitalized patients: results from a retrospective audit

Empirical use of temocillin in hospitalized patients: results from a retrospective audit

Measurement of vancomycin hydrochloride concentration in the exudate from wounds receiving negative pressure wound therapy: a pilot study

Temocillin: Applications in Antimicrobial Stewardship as a Potential Carbapenem-Sparing Antibiotic

Contact Info

Product

Resources

About